Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFD-03 (tazarotene) Lotion for Acne Vulgaris
NCT03290027Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jul 2017
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing Arazlo (DFD-03) Lotion with Vehicle Lotion (2 arms). Primary endpoints: Absolute Change in Inflammatory Lesion Counts on the Face at 12 weeks, Absolute Change in Non-inflammatory Lesion Counts on the Face at 12 weeks and 1 more. Started Jul 2017; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03290027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290027.